SHARE PURCHASE AGREEMENTShare Purchase Agreement • September 22nd, 2020 • Adagene Inc. • Pharmaceutical preparations • Hong Kong
NOW, THEREFORE, in consideration of the foregoing recitals, the mutual promises hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties intending to be legally bound hereto hereby agree as follows:
FIFTH AMENDED AND RESTATED SHAREHOLDERS AGREEMENT by and among ADAGENE INC. AND ITS SUBSIDIARIES ORDINARY SHAREHOLDERS NAMED HEREIN SERIES A SHAREHOLDERS NAMED HEREIN SERIES B SHAREHOLDERS NAMED HEREIN AND SERIES C SHAREHOLDERS NAMED HEREIN DECEMBER...Shareholder Agreement • September 22nd, 2020 • Adagene Inc. • Pharmaceutical preparations • Hong Kong
Each of the parties to this Agreement is referred to herein individually as a “Party” and collectively as the “Parties”. Capitalized terms used herein without definition shall have the meanings set forth in the Share Purchase Agreement (as defined below).
Dragon Boat Biopharmaceutical (Shanghai) Limited. AND Adagene Inc. Cooperation Agreement on International Interests of [***] Project May 2019Cooperation Agreement • September 22nd, 2020 • Adagene Inc. • Pharmaceutical preparations
This Cooperation Agreement on International Interests of [***] Project (this “Agreement”) is made and entered into by and among the following Parties on May 22, 2019 in Shanghai, the People’s Republic of China (“China” or the “PRC”):
FOURTH AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENTRight of First Refusal and Co-Sale Agreement • September 22nd, 2020 • Adagene Inc. • Pharmaceutical preparations • Hong Kong
Dragon Boat Biopharmaceutical (Shanghai) Limited. AND Adagene (Suzhou) Limited Cooperation Agreement on the [***] Project May 2019Cooperation Agreement • September 22nd, 2020 • Adagene Inc. • Pharmaceutical preparations
This Cooperation Agreement on the [***] Project (this “Agreement”) is made and entered into by and among the following parties on May 22, 2019 in Shanghai, the People’s Republic of China (“China” or the “PRC”):
Guilin Sanjin Pharmaceutical Co., Ltd. AND Adagene (Suzhou) Limited Cooperation Agreement on the PD-L1 Project December 2018Cooperation Agreement • September 22nd, 2020 • Adagene Inc. • Pharmaceutical preparations
This Cooperation Agreement on the PD-L1 Project (this “Agreement”) is made and entered into by and among the following parties on December 27, 2018 in Shanghai, the People’s Republic of China (“China” or the “PRC”):
Guilin Sanjin Pharmaceutical Co., Ltd. AND Adagene Inc. Cooperation Agreement on International Interests of PD-L1 Project December 2018Cooperation Agreement • September 22nd, 2020 • Adagene Inc. • Pharmaceutical preparations
This Cooperation Agreement on International Interests of PD-L1 Project (this “Agreement”) is made and entered into by and among the following Parties on December 27, 2018 in Shanghai, the People’s Republic of China (“China” or the “PRC”):
EMPLOYMENT AGREEMENTEmployment Agreement • September 22nd, 2020 • Adagene Inc. • Pharmaceutical preparations • New York
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of (the “Effective Date”), by and between Adagene Inc. a company incorporated and existing under the laws of the Cayman Islands (the “Company” and, together with all of its direct or indirect parent companies, subsidiaries, affiliates, or subsidiaries or affiliates of its parent companies, collectively referred to as the “Company Group”), and , an individual (the “Executive”).
